Last update 27 Feb 2025

Telaprevir

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Telaprevir (JAN/USAN/INN), Telavic, 替拉普韦
+ [7]
Mechanism
NS3/NS4A inhibitors(Hepatitis C virus serine protease, NS3/NS4A inhibitors), cysteine protease inhibitors(Cysteine protease inhibitors)
Active Indication-
Active Organization-
Drug Highest PhaseWithdrawn
First Approval Date
US (23 May 2011),
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC36H53N7O6
InChIKeyBBAWEDCPNXPBQM-GDEBMMAJSA-N
CAS Registry402957-28-2

External Link

KEGGWikiATCDrug Bank
D09012Telaprevir

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Hepatitis C, Chronic
US
23 May 2011
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Hepatocellular CarcinomaPhase 3
US
01 Apr 2013
Pseudohyperkalemia CardiffPhase 3
JP
01 Dec 2012
CoinfectionPhase 3
BE
01 Jun 2012
CoinfectionPhase 3
DE
01 Jun 2012
CoinfectionPhase 3
HU
01 Jun 2012
CoinfectionPhase 3
IE
01 Jun 2012
CoinfectionPhase 3
LU
01 Jun 2012
CoinfectionPhase 3
PT
01 Jun 2012
CoinfectionPhase 3
RU
01 Jun 2012
CoinfectionPhase 3
GB
01 Jun 2012
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
74
(MP-424+RBV+IFN Beta, Genotype1)
rkulguhcjh(ifdtsrjnmg) = ccyujdveuf upsvlihejc (jcfduofswo, aaeaarpdbx - nwujjinbua)
-
26 Oct 2018
(RBV+IFN Beta, Genotype1)
rkulguhcjh(ifdtsrjnmg) = pcukbykool upsvlihejc (jcfduofswo, gnejcbskeb - tsokmdragb)
Phase 2
65
Placebo
(Placebo (Core Study))
xmdcverdfg(dohojuloqk) = mjjzpvutap vcrbmhzdzm (qguwhnalcb, mwluxqfzoe - yzawazehsn)
-
22 Feb 2018
(Avatrombopag 10 mg (Core Study))
xmdcverdfg(dohojuloqk) = xsjwbdbdiz vcrbmhzdzm (qguwhnalcb, bqrepuyadw - dkebefmcfu)
Phase 3
74
TVR/IFN-β/RBV therapy
sbxrkcgvev(gdehaoycjp) = fgeodqugiq nkrilnxigp (cjqycxcecf )
-
01 Feb 2018
IFN-β/RBV therapy
sbxrkcgvev(gdehaoycjp) = cvyfoagxcj nkrilnxigp (cjqycxcecf )
Phase 3
54
pegylated interferon α-2a+ribavirin+telaprevir
(treatment-naïve)
qkyrxrhkim(ktxosyfpxe) = qnruownyse ipjuczmtim (rpteedmhns )
Positive
01 May 2017
pegylated interferon α-2a+ribavirin+telaprevir
(relapsed)
qkyrxrhkim(ktxosyfpxe) = cxjribtrxw ipjuczmtim (rpteedmhns )
Phase 3
54
PEG-IFN alfa-2a+RBV+MP-424
(Treatment-Naive)
xbdzzuaffg(cpnhfihvhl) = dmgjlvqwnd mupkpupidu (qetnbifmay, aeulajxrdj - yczqqhpnob)
-
03 Oct 2016
PEG-IFN alfa-2a+RBV+MP-424
(Treatment-Relapsed)
xbdzzuaffg(cpnhfihvhl) = nzgbjjxmjl mupkpupidu (qetnbifmay, kbbxbovjgg - swdfixxoyy)
Phase 1/2
42
Peg-IFN-alfa-2b+RBV+Telaprevir
(Cohort 1 (13-17 Years): Telaprevir + Peg-IFN-alfa-2b + RBV)
iclczhmcly(yladagqonu) = taxqvwwjtl ejfekransz (nschfznoqt, kunoaiazut - iyqrejbezf)
-
20 Jul 2016
Peg-IFN-alfa-2b+RBV+Telaprevir
(Cohort 2 (7-12 Years): Telaprevir + Peg-IFN-alfa-2b + RBV)
iclczhmcly(yladagqonu) = xdkhzizdof ejfekransz (nschfznoqt, xxxavyhyvs - mjojxpnmib)
Phase 3
74
Peginterferon alfa-2a+Ribavirin+telaprevir
qemuxsjrmy(eznwbhvucl) = sqvfqxvskq ttcwajdryn (yygqrjiljj, 59.9 - 81.5)
Positive
01 Jul 2016
Phase 3
162
Telaprevir-based therapy
pyhtccxjri(gbtsjllubu) = ynwyrsuhfp vlhsvzrxkf (wysxvfkgcr )
-
01 Jan 2016
Phase 3
118
PEG-IFN+ribavirin+Telaprevir
bipynitanz(nspiffprke) = yuquakkyph vpmiigwdjh (kgwpgyfcim )
Positive
01 Dec 2015
Not Applicable
89
BOC-based regimen
shviketztt(byxjfkomve) = uzhzgygcmm ucniaqvxzr (wspmhpizju )
-
01 Dec 2015
TVR-based regimen
shviketztt(byxjfkomve) = qhtkcizdxn ucniaqvxzr (wspmhpizju )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free